Navigation Links
AlphaRx and Venturepharm Announce Collaboration Agreement
Date:8/4/2009

MARKHAM, ON, Aug. 4 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTC BB:ALRX.OB - News), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, today announced that the Company has entered into a collaboration agreement with Venturepharm Group (the "Venturepharm") to establish a drug development center in China Medical City, Taizhou, China that is expected to be used as a platform for the development of innovative drug products for the fast growing China pharmaceutical market. The goal of this is to enhance the Company's research capabilities, expedite the development of new products as well as to expand the Company's product range.

Under the terms of the agreement, AlphaRx will incorporate its China R D facility into Venturepharm's state of the art pre-clinical development complex which comprises of a 200,000 sq. ft. chemistry center, a 200,000 sq. ft. multi-product pilot plant to support pilot scale formulation and Clinical Trial Material (CTM) manufacture of biopharmaceutical products and a 500,000 sq. ft. (Asia's largest) animal testing center (under construction). The in-house pharmaceutical research facilities provide specialized equipment for most aspects of drug research and development. AlphaRx will be responsible for all of its own product development costs and will in turn retain the intellectual property rights relating to any developed products.

Michael Lee, President of AlphaRx, said: "Venturepharm provides the equipment and physical infrastructure to further establish our presence in China and reduces our start up investment costs. As AlphaRx continues to build its presence in China, this collaboration with Venturepharm marks an important step in our overall strategy to commercialize current products and to develop new therapeutics for the world fastest growing pharmaceutical market."

About AlphaRx Inc.

AlphaRx is a specialty pharma
'/>"/>

SOURCE AlphaRx Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. AlphaRx Presents Positive Preclinical Data on Zysolin(TM) Inhalable Nanoparticles at Controlled Release Society Annual Meeting
2. AlphaRx Unveils its China Strategy
3. AlphaRx Reports Positive Preclinical Data on GAI-122 Against Liver Disease
4. AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
5. AlphaRx Shareholder Update
6. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
7. AlphaRx Signs Cooperative Research and Development Agreement with US Army
8. AlphaRx Provides Corporate and Development Update
9. AlphaRxs Indaflex(TM) Continues its Clinical Development
10. AlphaRx CEO Accumulates More Company Shares
11. AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...A team of Kendall Hunt authors earned the 2009 Gif... recent National Association for Gifted Children&r...7, 2009. , Dubuque, IA (P...uthors earned the 2009 Gifted Child Quarterly Pape...tion for Gifted Children’s annual conference...
(Date:12/2/2009)...s Washington Post Highlights Dangers ,, ...f the Catholic bishops have their way, many medica... granted may be under threat. The pressure that t...ver healthcare reform has been widely reported. An...he likely impact if that pressure to influence hea...
(Date:12/2/2009)...d in birth defect that affects male urethra, resea...Day News) -- Male babies of women who use insect r...cy appear to be at increased risk for a birth defe...is birth defect, which affects about two of every ... the urethra, the tube that carries urine from the...
(Date:12/2/2009)...ike unlikely heroes in the battle against drug abu...already used to study dozens of human disease cou...fruit flies can be used as a simpler and more conv...caine and other drugs of abuse on the brain. Their...e , a new monthly journal. , Andrew Ewing and c...
(Date:12/2/2009)...MyCareTeam, Inc., a leading vendor of Internet-bas...ed the newest version of its software offering. T...ve heart failure and weight management capabilitie...features. , Acton, MA. ...ading vendor of Internet-based chronic disease man...
Breaking Medicine News(10 mins):Health News:Kendall Hunt Authors Earn NAGC “Paper of the Year” Award 2Health News:Everybody's Healthcare Is Threatened by Catholic Bishops' Interference 2Health News:MyCareTeam™ Significantly Extends Diabetes Offering to Include Management of Hypertension, Obesity, and Congestive Heart Failure 2
...sease are more likely to have a specific variant o...arried out tests on 500 men who had died suddenly,... found that, in men younger than 55, a gene varian... Men with HPA-2 Met have blood that is 'stickier' ...
...tain over-the-counter pain killers should carry wa...age. The comments follow a study by Danish re...hed in this week's British Medical Journal which s...records to identify a study group of pregnant wome...
...anufactured by Bayer Pharmaceuticals. Baycol, whic...statin group of drugs that lowers cholesterol by b...s of cholesterol in the body. Bayer Pharmaceu... a muscular side effect called rhabdomyolysis – de...
...iversity of north Carolina at Chapel Hill, state ...t genetic instructions into action. The U...ical site on a key enzyme that regulates productio...n DNA,is converted into functions critical for mai...
...ncer, a single raw clove of garlic can do wonders...Garlic is best known for staying off heart disease... A substance called diallyl disulfide in garlic is...de to rats and found it increased levels of the ca...
...a genetically engineered drug called NATRECOR to e... failure patients. Congestive heart failure is...gh blood to meet the needs of the body's other org...d Drug Administration approved an injection of Nat...
Other Medicine News:
(Date:12/2/2009)... Dec. 2 PDL BioPharma, I... has established the per share amount of the previ...1.67 per share. The dividend will be paid on Decem... as of the December 1, 2009 record date. NASDAQ ha...mount of the dividend at $1.67 per share of common...
(Date:12/2/2009)...ec. 2 Roche (SIX: RO, RO...tates Food & Drug Administration (FDA) approve...eic acid test, to screen source plasma in pools co..., called the cobas® TaqScreen MPX Test for us...n-vitro test for the simultaneous, direct detectio...
(Date:12/2/2009)...a, Dec. 2 /PRNewswire-Asia/ -- Simcere Pharmaceuti...R ), a leading pharmaceutical company,specializing...of branded,generic and proprietary pharmaceuticals...gsu Yanshen Biological Technology Stock Co., Ltd. ...l its products in order to conduct an,internal ins...
Breaking Medicine Technology:PDL BioPharma Announces December 15 Special Dividend Payment of $1.67 per Share 2PDL BioPharma Announces December 15 Special Dividend Payment of $1.67 per Share 3FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production 2Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production 3Rate of teen binge drinking cut more than 1 3 by prevention system 56343 1Rate of teen binge drinking cut more than 1 3 by prevention system 56343 2Rate of teen binge drinking cut more than 1 3 by prevention system 56343 3Even Mild Infections Hasten Decline With Alzheimers 56340 1Even Mild Infections Hasten Decline With Alzheimers 56340 2Even Mild Infections Hasten Decline With Alzheimers 56340 3Genomes reveal bacterial lifestyles 3A Research 9817 1Genomes reveal bacterial lifestyles 3A Research 9817 2
...INESS WIRE)--Jun 12, 2007 - Results from the,succe...Nasdaq:,OSCI) FACTIVE(R) (gemifloxacin mesylate) t...uired pneumonia of mild to moderate,severity (CAP)...-reviewed Journal of Antimicrobial Chemotherapy, c...om the Phase III clinical,trial comparing a five-d...
...SINESS WIRE)--Jun 12, 2007 - Proprietary Pulsed,El...y Ivivi,Technologies, Inc. (AMEX:II), improved neu...ain inflammation, researchers,reported today in a ...ociety (BEMS,http://www.bioelectromagnetics.org) ...s associated with neuron death that occurs in,Park...
Other Medicine Technology:July Issue of Journal of Antimicrobial Chemotherapy Highlights,Study of Factive Tablets for Five-Day Treatment of,Community-Acquired Pneumonia 2July Issue of Journal of Antimicrobial Chemotherapy Highlights,Study of Factive Tablets for Five-Day Treatment of,Community-Acquired Pneumonia 3July Issue of Journal of Antimicrobial Chemotherapy Highlights,Study of Factive Tablets for Five-Day Treatment of,Community-Acquired Pneumonia 4July Issue of Journal of Antimicrobial Chemotherapy Highlights,Study of Factive Tablets for Five-Day Treatment of,Community-Acquired Pneumonia 5Ivivi's PEMF Technology Significantly Improves Neuron Survival in,Parkinson's Disease Model, Study Finds 2Ivivi's PEMF Technology Significantly Improves Neuron Survival in,Parkinson's Disease Model, Study Finds 3
PocketPractitioner™ Office
Archimedes™
Prentice Hall Nurse's Drug Guide 2006
Physician's Drug Handbook, 10th Ed
Medicine Products: